Lucid Diagnostics (LUCD) Shares Outstanding (2020 - 2026)

Lucid Diagnostics (LUCD) has reported Shares Outstanding (Entity) for 7 consecutive years, with $190.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 87.33% year-over-year to $190.8 million; the trailing twelve-month figure through Jun 2026 stood at $190.8 million (up 87.33% YoY), and the FY2025 full-year result was $101.9 million, up 101.81% from the prior year.
• Shares Outstanding (Entity) rose to $190.8 million in Q2 2026 per LUCD's latest filing, from $164.9 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $190.8 million in Q2 2026 and bottomed at $35.2 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $69.5 million across 5 years, with a median of $48.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 162.25% in 2022, then advanced 4.47% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $40.5 million in 2022, then rose by 4.47% to $42.3 million in 2023, then gained by 19.34% to $50.5 million in 2024, then jumped by 101.81% to $101.9 million in 2025, then surged by 87.11% to $190.8 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $190.8 million, $164.9 million, and $101.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.